Pfizer says COVID-19 vaccine trial more than 50 percent enrolled


NEW YORK, Aug 26 (Reuters) - Enrollment in the 30,000-volunteer U.S. trial testing a COVID-19 vaccine from Pfizer Inc PFE.N and German partner BioNTech is more than 50 percent complete, Dr. Nicholas Kitchin, a top Pfizer vaccine research and development scientist, said at the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices meeting on Wednesday.

Last week, the company said it had enrolled more than 11,000 volunteers in the trial.

(Reporting by Michael Erman Editing by Chizu Nomiyama)

((; +1 646-223-6021; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.